New York-based biotechnology firm plans for future development by hiring healthcare financier Patrick Gallagher
Patrick Gallagher has been appointed by Kinex Pharmaceuticals, a US biotechnology firm focused on next-generation therapies in oncology and immunology, to the position of vice president of business development and investor relations. He will report to the company’s CEO, Dr Johnson Lau.
Gallagher has 20 years of experience in healthcare and specialty chemical research and institutional sales. He is also an early investor in Kinex and a managing director of Potomac Management Group, a strategic consulting group.
In 2001 Gallagher founded BDR Research, an independent sell-side research firm specializing in the healthcare space. Prior to this, he held various institutional sales positions at Kidder Peabody, PaineWebber and New Vernon Associates. In 2010 he was appointed by broker Concept Capital, a division of Sanders Morris Harris, to serve as head of institutional sales.
Gallagher is a CFA charter holder. He holds a BS in finance from the University of Vermont and an MBA from Pennsylvania State University.
Commenting on the hire, Dr Lau says in a press release: ‘I am delighted to welcome Pat Gallagher’s deep insight and expertise in the biotechnology space, which will be instrumental in helping us to plan for our next phase of company growth.’
Such comments strongly hint that the company, which is privately owned, may be contemplating an IPO in the near future.
Candice de Monts-Petit
Candice de Monts-Petit joined IR Magazine as a senior editor in 2012. Prior to this, she worked in investor relations, first as an IRO for oil and gas firms in Paris and Moscow and subsequently as an IR consultant in London. She graduated in business...
